Targeted agents, including epidermal growth factor receptor (EGFR) inhibitors such as cetuximab and panitumumab and vascular endothelial growth factor (VEGF) inhibitors such as bevacizumab, provide clinical benefits by disrupting critical oncogenic pathways involved in tumor progression and metastasis (6, 7). Here, EGFR is linked to neoplasm.